Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Bonnie Mohler

Nurse Practitioner, Adult Health Canton, OH Nurse Practitioner

NPI 1972761278 CMS profile 11056168

4665 Belpar St Nw, Canton, OH 44718

Open in the dashboard

General payments

$338,005

1,817 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bonnie Mohler of Canton, OH is reported in the CMS Open Payments database as having received $338,005 across 1,817 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $115,745 355
2024 General $76,606 389
2023 General $44,945 264
2022 General $59,894 377
2021 General $40,815 432

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bonnie Mohler
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Bonnie Mohler were reported at $115,745. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Bonnie Mohler Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $40,815 $138 $43–$438 $132
2022 $59,894 $165 $54–$494 $149
2023 $44,945 $178 $61–$549 $160
2024 $76,606 $186 $62–$575 $164
2025 $115,745 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $62,771 169 payments
  2. Phathom Pharmaceuticals, Inc. $59,993 159 payments
  3. Intercept Pharmaceuticals, Inc. $50,479 111 payments
  4. Evoke Pharma, Inc. $49,887 97 payments
  5. AbbVie, Inc. $40,018 378 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $23,077 189 payments
  7. Madrigal Pharmaceuticals $18,743 41 payments
  8. Ipsen Biopharmaceuticals, Inc $16,808 39 payments
  9. Ardelyx, Inc. $5,402 70 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $1,469 78 payments
  11. Other $9,358 486 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $194,073 177 payments
  2. Travel and Lodging $60,416 133 payments
  3. Food and Beverage $35,606 1,457 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $33,945 29 payments
  5. Consulting Fee $7,858 6 payments
  6. Honoraria $5,843 8 payments
  7. Education $264 7 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $61,346 106 payments
  2. VOQUEZNA $59,929 153 payments
  3. GIMOTI $48,004 94 payments
  4. OCALIVA Hepatology / Gastroenterology $42,911 88 payments
  5. CREON $20,882 121 payments
  6. XIFAXAN $18,304 138 payments
  7. IQIRVO $16,774 37 payments
  8. REZDIFFRA $15,668 34 payments
  9. STELARA $14,040 80 payments
  10. OCALIVA Hepatology Gastroenterology $7,569 23 payments
  11. Other $30,861 1,133 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 57 drugs

Part D claims

6,189

Median for Nurse Practitioner: 389

Drug cost

$1,691,397

Median for Nurse Practitioner: $21,885

Branded share of claims

28.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 52 $385,710
Ocaliva Obeticholic Acid Brand 19 $235,819
Zenpep Lipase/Protease/Amylase Brand 32 $147,666
Xifaxan Rifaximin Brand 44 $133,983
Linzess Linaclotide Brand 153 $125,657
Creon Lipase/Protease/Amylase Brand 28 $103,968
Dexlansoprazole Dr Dexlansoprazole Brand 354 $83,724
Gimoti Metoclopramide Hcl Brand 33 $66,915
Mesalamine Generic 94 $54,953
Ibsrela Tenapanor Hcl Brand 19 $39,266

The 10 drugs with the highest cost, of 57 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$34,111

Medicare's payments for the services billed

Medicare patients

424

Average age 73

Services billed

616

269 women, 155 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 30%
Depression 27%
Diabetes 25%
Chronic kidney disease 21%
Atrial fibrillation 18%
Cancer 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
$44,047 43 —
GIMOTI
$7,582 33 —
STELARA
$6,267 — —
TREMFYA
$6,163 — —
CREON
$2,727 28 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

1,817 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record